Home
Companies
Catalysts
Deep Dives
Opevesostat
MK-5684
PHASE3
Drug Profile
Modality
Small molecule
Route
PO
Therapy Area
Oncology
Peak Sales Est
$2000M
Formulations
[]
Companies
MRK
(ORIGINATOR)
100%
Mechanism: AKR1C3 inhibitor
Expert:
Aldo-keto reductase 1C3 inhibitor blocking intratumoral androgen synthesis
Everyday:
Blocks enzyme that helps prostate cancer grow
Targets: ["AKR1C3"]
Notes
AKR1C3 inhibitor for prostate cancer. Novel mechanism post-AR targeting.
Data from Supabase · Updated 2026-03-24